Ultomiris Used for 1st Time to Manage aHUS During Kidney Transplant
Ultomiris (ravulizumab) was reportedly used for the first time to control atypical hemolytic uremic syndrome (aHUS) in a patient who received a kidney transplant from a living donor, according to a group of doctors in Germany. “We provide first evidence for the efficacy of [Ultomiris] to prevent recurrence…